Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

801. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose: a meta-analysis

Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

802. Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature

Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature Archbold R A, Schilling R J CRD summary This review attempted to assess the use of pacing to prevent irregular heart (...) rhythms after coronary bypass surgery. The authors concluded that biatrial pacing was effective, but that there is insufficient evidence pertaining to single atrial pacing. Methodological weaknesses and poor reporting of the review process mean that the conclusions should be treated with caution. Authors' objectives To critically review the trial evidence regarding the efficacy of epicardial atrial pacing (AP) to prevent post coronary artery bypass graft (CABG) atrial fibrillation (AF). Searching

2004 DARE.

803. Systematic review of intraoperative ablation for the treatment of atrial fibrillation

Systematic review of intraoperative ablation for the treatment of atrial fibrillation Systematic review of intraoperative ablation for the treatment of atrial fibrillation Systematic review of intraoperative ablation for the treatment of atrial fibrillation Hazel S J, et al CRD summary This review assessed the efficacy and safety of intra-operative surgical ablation in the treatment of atrial fibrillation. The authors concluded that intra-operative ablation is at least as effective as surgery (...) alone or the Maze-III procedure. The lack of evidence from randomised controlled trials and the poor quality of the available evidence justify the limited conclusions; however, some of the review methods were unclear. Authors' objectives To assess the safety and efficacy of intra-operative ablation techniques for the treatment of atrial fibrillation (AF). Searching MEDLINE, EMBASE, the Cochrane Library, the Science Citation Index, ClinicalTrials.gov, the NHS Centre for Reviews and Dissemination

2004 DARE.

804. Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery

Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Reddy P, Kalus J S, Caron M F, Horowitz (...) S, Karapanos A, Coleman CI, Kluger J, White C M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four alternative prophylactic strategies for preventing atrial fibrillation (AF) in patients undergoing open heart surgery were

2004 NHS Economic Evaluation Database.

805. Warfarin in the secondary prevention of thromboembolsim in atrial fibrillation: impact of bioavailability on costs and outcomes

Warfarin in the secondary prevention of thromboembolsim in atrial fibrillation: impact of bioavailability on costs and outcomes Warfarin in the secondary prevention of thromboembolsim in atrial fibrillation: impact of bioavailability on costs and outcomes Warfarin in the secondary prevention of thromboembolsim in atrial fibrillation: impact of bioavailability on costs and outcomes Mittmann N, Oh P I, Walker S E, Bartle W R Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several warfarin products with different bioavailability (F) for the prevention of thromboembolism in atrial fibrillation were examined. Strategy 1 was warfarin with F=1 (brand warfarin). Strategy 2 was warfarin with F=0.80. Strategy 3 was warfarin with F

2004 NHS Economic Evaluation Database.

806. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis

The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis Gerson L B, Triadafilopoulos G, Gage B F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Seven strategies for the management of anticoagulants in the periendoscopic period for patients with atrial fibrillation were investigated. The strategies were as follows. Continue warfarin: a colonoscopy was performed without interrupting warfarin therapy. Hold warfarin

2004 NHS Economic Evaluation Database.

807. Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation

Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Coleman C I, Kalus J S, White C M, Spencer A P, Tsikouris J P, Chung J O, Kenyon K W, Ziska M, Kluger J, Reddy P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of ibutilide in the presence and absence of magnesium prophylaxis for the conversion of atrial fibrillation (AF). The mean dose of ibutilide was 2.2 (+/- 1) g. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

2004 NHS Economic Evaluation Database.

808. Cost-effectiveness of rhythm versus rate control in atrial fibrillation

Cost-effectiveness of rhythm versus rate control in atrial fibrillation Cost-effectiveness of rhythm versus rate control in atrial fibrillation Cost-effectiveness of rhythm versus rate control in atrial fibrillation Marshall D A, Levy A R, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene H L, Wyse D G, Nichol G, O'Brien B J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study considered the treatment of atrial fibrillation (AF) using rhythm versus rate control. Rhythm control was defined as electrical cardioversion, anti-arrhythmic drugs and nonpharmacologic therapies (e.g. multisite atrial pacing, maze procedures or radiofrequency ablation procedures) to maintain sinus rhythm. Rate control used

2004 NHS Economic Evaluation Database.

809. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan Full Text available with Trip Pro

Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan Maeda K, Shimbo T, Fukui T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology An annual electrocardiogram (ECG) community-based screening programme and an annual pulse palpation community-based screening programme for chronic atrial fibrillation (AF) were compared with no screening. Different screening intervals and starting ages (65 or 75 years) were also evaluated. Type of intervention Screening. Economic study type Cost

2004 NHS Economic Evaluation Database.

810. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. (Abstract)

Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. The Joint Panel of the American Academy of Family Physicians and the American College of Physicians, in collaboration with the Johns Hopkins Evidence-based Practice Center, systematically reviewed the available evidence on the management of newly detected atrial fibrillation and developed recommendations for adult patients (...) with first-detected atrial fibrillation. The recommendations do not apply to patients with postoperative or post-myocardial infarction atrial fibrillation, patients with class IV heart failure, patients already taking antiarrhythmic drugs, or patients with valvular disease. The target physician audience is internists and family physicians dedicated to primary care. The recommendations are as follows: RECOMMENDATION 1: Rate control with chronic anticoagulation is the recommended strategy for the majority

2003 Annals of Internal Medicine

811. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. (Abstract)

Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. This review summarizes the available evidence regarding the efficacy of medications used for ventricular rate control, stroke prevention, acute conversion, and maintenance of sinus rhythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patients with atrial fibrillation.The Cochrane Collaboration's database (...) of controlled clinical trials and MEDLINE.Primarily randomized, controlled trials of medications.Paired reviewers obtained data on efficacy and safety. Strength of evidence was assessed.Recent clinical trial results showed that most patients with atrial fibrillation have similar outcomes with strategies for controlling ventricular rate compared with strategies for restoring sinus rhythm. For efficacy of primary stroke prevention, compared with placebo, evidence was strong for warfarin and suggestive

2003 Annals of Internal Medicine

812. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. (Abstract)

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR.We studied incident ischemic (...) strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation. Strokes were identified through hospitalization data bases and validated on the basis of medical records, which also provided information on the use of warfarin or aspirin, the INR at admission, and coexisting illnesses. The severity of stroke was graded according to a modified Rankin scale. Thirty-day mortality was ascertained from hospitalization and mortality files.Of 596 ischemic strokes, 32 percent occurred during

2003 NEJM

813. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. Full Text available with Trip Pro

A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. Prior risk stratification schemes for atrial fibrillation (AF) have been based on randomized trial cohorts or Medicare administrative databases, have included patients with established AF, and have focused on stroke as the principal outcome.To derive risk scores for stroke alone and stroke or death in community-based individuals with new-onset

2003 JAMA

814. Lessons from the Stroke Prevention in Atrial Fibrillation trials. (Abstract)

Lessons from the Stroke Prevention in Atrial Fibrillation trials. Atrial fibrillation predisposes to left atrial thrombus formation and carries a sixfold increased risk for stroke. Antithrombotic therapies are the mainstay for stroke prevention. The National Institute of Neurological Disorders and Stroke-sponsored Stroke Prevention in Atrial Fibrillation (SPAF) studies assessed the value of warfarin, aspirin, and their combination for preventing stroke in six multicenter trials involving 3950 (...) participants. This review presents the major results and implications, which offer unique perspectives on antithrombotic therapies for stroke prevention in atrial fibrillation. Warfarin and aspirin reduce stroke. Anticoagulation substantially benefits high-risk patients with atrial fibrillation, while many younger patients with atrial fibrillation have a low stroke rate when given aspirin. Pathogenetic and transesophageal echocardiographic correlations shed light on mechanisms by which antithrombotic

2003 Annals of Internal Medicine

815. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. (Abstract)

Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Pulmonary vein isolation is a new, effective curative procedure for selected patients with atrial fibrillation. Pulmonary vein stenosis is a potential complication and may lead to symptoms that are often underrecognized.To describe the clinical course and symptoms associated with pulmonary vein stenosis developing after ablation in the pulmonary veins.Retrospective study.Tertiary care (...) ). Pulmonary vein stenosis was not considered in any patient during the initial work-up. Dilatation of the affected vein was performed in 12 patients. Postintervention lung perfusion scans revealed significant improvement in lung flow.Severe pulmonary vein stenosis after catheter ablation of atrial fibrillation is associated with respiratory symptoms that frequently mimic more common diseases, often leading to erroneous diagnostic and therapeutic procedures. Awareness of this syndrome is important

2003 Annals of Internal Medicine

816. Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation

Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Institute for Clinical Systems Improvement. Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2003 Authors' objectives This review aims to assess the available evidence on rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation (AF). Authors' conclusions With regard to rhythm therapy versus rate control for long-term management of recurrent atrial

2003 Health Technology Assessment (HTA) Database.

817. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. (Abstract)

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Warfarin prevents ischaemic stroke in patients with non-valvular atrial fibrillation, but dose adjustment, coagulation monitoring, and bleeding risk limit its use. The oral direct thrombin inhibitor ximelagatran represents a potential alternative. We aimed to establish whether ximelagatran is non-inferior (...) to warfarin, within a margin of 2% per year, for prevention of stroke and systemic embolism.We randomised 3410 patients with atrial fibrillation and one or more stroke risk factors to open-label warfarin (adjusted-dose, international normalised ratio [INR] 2.0-3.0) or ximelagatran (fixed-dose, 36 mg twice daily); patients were recruited from 259 hospitals, doctor's offices, or health-care clinics. Primary analysis was based on masked event assessment and was by intention to treat. Primary endpoint

2003 Lancet Controlled trial quality: predicted high

818. Temporary atrial epicardial pacing as prophylaxis against atrial fibrillation after heart surgery: a meta-analysis

Temporary atrial epicardial pacing as prophylaxis against atrial fibrillation after heart surgery: a meta-analysis Temporary atrial epicardial pacing as prophylaxis against atrial fibrillation after heart surgery: a meta-analysis Temporary atrial epicardial pacing as prophylaxis against atrial fibrillation after heart surgery: a meta-analysis Daoud E G, Snow R, Hummel J D, Kalbfleisch S J, Weiss R, Augostini R CRD summary This review assessed the short-term use of pacemakers to prevent atrial (...) fibrillation after heart surgery. The authors concluded that evidence supports the use of pacemakers. The review had a limited search, review methods were not always reported and there was some confusion about numerical values in the paper. These factors make it difficult to assess the reliability of the conclusions. Authors' objectives To assess the effect of pacing therapies for the prevention of new-onset atrial fibrillation following cardiac surgery. Searching MEDLINE, bibliographies of identified

2003 DARE.

819. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis

Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P CRD summary This well reported review compared amiodarone with placebo (...) or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Even though the onset of conversion was delayed, the efficacy of amiodarone was similar at 24 hours compared with class Ic drugs. The conclusions reached by the authors seem valid and the limited generalisability of the findings was acknowledged. Authors' objectives To conduct a meta-analysis comparing amiodarone with placebo or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Searching

2003 DARE.

820. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis

Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.